Alterity Therapeutics Ltd. has released a press release.
ATH Receives A$3.98m R&D Tax Incentive
Earlier from Alterity Therapeutics
- Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
- FDA Meeting Minutes Confirm Registrational Path for ATH434
- Alterity Therapeutics: Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy